Home › Funds › Intermede Investment Partners Ltd › VRTX
Intermede Investment Partners Ltd position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
Intermede Investment Partners Ltd reported holding 101,619 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$51.5M, representing 2.17% of its reported portfolio and ranking #22 among its reported holdings. Intermede Investment Partners Ltd has disclosed VRTX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Intermede Investment Partners Ltd's VRTX position evolved
Intermede Investment Partners Ltd first disclosed a stake in VRTX in Q1 2025 at 204,045 shares (US$98.9M). Across 6 filings, Intermede Investment Partners Ltd increased the stake 0 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 101,619 shares valued at US$51.5M — a reduction of -4,751 shares quarter over quarter.. Notable position changes include a 28% trim in Q3 2025 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 204.04K | $98.92M | New |
| Q2 2025 | 193.91K | $86.33M | Reduce |
| Q3 2025 | 140.02K | $54.84M | Reduce |
| Q4 2025 | 133.38K | $60.47M | Reduce |
| Q1 2026 | 106.37K | $47.50M | Reduce |
| Q2 2026 | 101.62K | $51.50M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Invesco Ltd 8.04M sh · $4.00B · Q2 2026
- LOOMIS SAYLES & CO L P 3.92M sh · $1.95B · Q2 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- Clearbridge Investments, LLC 2.34M sh · $1.16B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.17M sh · $1.08B · Q2 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on Intermede Investment Partners Ltd
FAQ
How long has Intermede Investment Partners Ltd held VRTX?
Intermede Investment Partners Ltd has disclosed VRTX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is Intermede Investment Partners Ltd's current position in VRTX?
As of Q2 2026, Intermede Investment Partners Ltd holds 101.62K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $51.50M, representing 2.17% of its reported portfolio and ranking #22.
Has Intermede Investment Partners Ltd been buying or selling VRTX?
In the latest 13F filing (Q2 2026), Intermede Investment Partners Ltd reduced its position in VRTX.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.